Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Revenue of Entrada Therapeutics, Inc. (TRDA)
Revenue in 2023 (TTM): $129.01 M
According to Entrada Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $129.01 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Entrada Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $129.01 M | $29.13 M | $-321,000 | $12.06 M | $-6,685,000 |
| 2022 | $ | $-1,895,000 | $-95,353,000 | $-94,616,000 | $-87,457,000 |
| 2021 | $ | $-1,117,000 | $-50,010,000 | $-51,158,000 | $-50,072,000 |
| 2020 | $ | $-326,000 | $-26,341,000 | $-26,523,000 | $-26,379,000 |
| 2019 | $ | $-104,000 | $-11,720,000 | $-5,100,000 | $-4,649,000 |